Bristol-myers Squibb Compnay

Mendi A Higgins

Lawrence R Marcin

John E Macor

Yong-Jin Wu

Eric Mull

Graham S Poindexter

Jianliang Shi

Lorin A Thompson, Iii

Xiang-Yang Ye

Christian L Morales

Joanne J Bronson

Ronald J Mattson

Min Ding

Kenneth M Boy

Kevin W Gillman

James Breitenbucher

Ramkumar Rajamani

Dalton King

John D Catt

Yunhui Zhang

F Christopher Zusi

Jason M Guernon

Jonathan L Ditta

James R Epperson

Derek John Denhart

Jeffrey A Deskus

Leah M Giupponi

Ildiko Antal

Robert H Stoffel

Lorin A Iii Thompson

The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;V-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of &#x3b1;V-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Indazole derivatives as alpha v integrin antagonists

The present invention provides compounds of Formula (Ia) or (Ib): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;V-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of &#x3b1;V-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

Indazole derivatives as &#x3b1;v integrin antagonists

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system. 

Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: 

Compounds for the reduction of beta-amyloid production

The present disclosure provides a series of compounds of the formula (I) which reduce &#x3b2;-amyloid peptide (&#x3b2;-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by &#x3b2;-amyloid peptide (&#x3b2;-AP) production.

Bicyclic compounds for the reduction of beta-amyloid production

A series of N-cycloalkylcarboxamide derivatives of N-benzyl benzenesulfonamides of Formula I are described.  The compounds inhibit &#x3b2;-amyloid peptide (&#x3b2;-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions characterized by aberrant extracellular deposition of &#x3b2;-amyloid. Pharmaceutical compositions and methods of treatment using these compounds are also disclosed.

Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives

Cyclopropylindole derivatives as selective serotonin reuptake inhibitors

Oxadiazole and thiadiazole derivatives of dihydropyridine NPY antagonists

A series of non-peptidergic antagonists of NPY have been synthesized and are comprised of phenyl derivatives of imidazolone compounds of Formula I. ##STR1## As antagonists of NPY-induced feeding behavior, these compounds and known analogs are expected to act as effective anorexiant agents in promoting weight loss and treating eating disorders.

Imidazolone anorectic agents: II. phenyl derivatives

Growing community of inventors

Meriden, CT, United States of America

Mendi A Higgins